200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D

C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura, 2008 27 2 4 2 C Imamura, 2008 TRPM8 Chen, 2009; Zhang, 2012 TRPM8 Noguchi, 2013 Imamura, 2013 C TRPM8 Imamura, 2013

20 2014 11 2015 10 1 685 292 393 64 15 93 183 111 42 40 40 34 28 24 18 17 15 15 15 46 77 36 33 30 19 31 150 36 34 30 17 12 10 10 38 20 A 230 B 93 C 71 D 50 E 44 5 488 71 A 31 B 24 10 20 1 28 56 155.5cm 52.2kg 17 H7 30 2 9 5 20 10 1 2 H16/4/6 S GIF 5g H19/3 4/18 UFM 74ml 8.2ml/s US H19/4/18 1 1 6/27 15g 11 H22/2/3 H26/11 H27/3/31 H27/9 12/8 K K 8

/ 2 13 7.5g 1 3 BPSD Behavioral and Psychological Symptoms of Dementia DRS Delirium Rating Scale / / 8 5 83 88 28% 0% BPSD DRS / 2013 robot-assisted radical prostatectomy: RARP RARP 2013 8 2015 12 RARP 178 RARP

LOH 2014 4 2015 12 59 Aging male s symptoms AMS T luteinizing hormone LH follicle-stimulating hormone FSH 52.4 9.5 506 214ng/dL, LH 5.2 3.6 miu/ml 37 62.7% 13 22.0% 9 12.3% 17 32.7% 35 67.3% 15 25.4% 25 42.4 19 32.2 24 54.6% 20 45.4 421 vs.603, P = 0.023 64 vs.42 %, P= 0.127 12 5 3 2 2 1 LOH ESWL TUL PNL 30 1 2 5 ESWL 27 5 1 7 31 14 27 10 31 49 43, 61.25 11 3 BMI 23.15 kg/m2 20.26, 27.8 5mm 3.75, 10 4 10mm R2 1 R3 2 U1 5 U2 2 U3 4 30 28, 33 107.5 53.75, 132 14 8 57.1% 5mm 6 3 50.0% 10mm 4 3 75.0% 14

2014 5 CRPC 12.8% 21.5% 2014 6 196 1172 Cancer Fatigue Scale CFS CRPC CFS 72 PSA1765ng/ml Gleason score4+4 adenocarcinoma CT 1 3 CRPC 3 8 PSA 2 CFS CFS 36 4 CFS 20 PSA 7 1 77 C 2013 9 PSA3122ng/ml ct4n0m1 multiple OSS Gleason Score 4+4 10 CAB 12 2014 3 8 PSA Nadir 9 10 2015 1 Nadir 1.675ng/ml 2 PSA 0.8 1.9 2015 6 Fe 135 g/dl 238ng/ml Alb 4.2g/dL 3 2 71 2013 PSA7.7ng/ml 8 ct2 N0M0 Gleason Score 3+3 high risk 11 CAB 2014 1 AST 167U/L/ALT 312U/L CAB 7 2015 1 PSA12.467ng/ml MRI T3a 3 2 AST 729U/L ALT 719U/L ALP 1189U/L GTP 627U/L 3.2mg/dL CT 1 AST 32 ALT 75 LDH 179 ALP 745 GTP 365 1 PSA

89 CEA Urothelial Carcinoma, high grade, pt2b, CEA 6 CEA CT 4 CEA CT stable disease SD 15 6 9 4 2 3 5 1 69.5 5.3 2.3 0.6 MSKCC 7 7 1 Karnofsky Performance Status KPS 90.0 8.5 7.9 2.1 25.0-50.0 41.7 7.7 mg 2 1 15 12 80.0% CTCAE v4.0 G2:8 G3:4 2.5g*3 30 30 KPS Hb 01 2 3 4 p<0.05 KPS 90.0 8.5 86.0 6.3 p=0.009 2.1 0.7 1.5 0.5 p=0.0001 54.0 9.2 53.0 8.7kg p=0.021 4.2 0.4 4.0 0.4g/dL p=0.008 Hb 12.2 0.8 12.0 0.6g/dL 3.9 0.4 1.8 0.9 p=0.0001 1 5 2.5 2.5 2.5 2.5 2.5 1.0 PGE2

SD 0.04 / 0.1% 1% / 4 1% 1% 1% 1% Pelvic Congestion model; PC PC SD PC Sham 2 1 1 4 NOx Real time RT-PCR enos nnos mrna Sham PC PC PC NOx Sham PC enos nnos mrna PC enos mrna Sham 2 2 NOx

2007 49 28 20 1 1 7.5 3 24 2distigmine,bethanechol,tramsulosin 9 3 distigmine,bethanechol,urapidil 16 3 retrospective 32 14 8 2 4 9 4 1 24 14 58 2 9 8 1 2 33 22 67 3 16 12 75 bethanechol NSAIDs 39 G1P0 20 30 600mg 1800mg 2 5g 3/day 1 7.5g/day off 7.5g/day 7.5g/day 600mg/day 36 1

27 4 2 3 1 16 11 14 10 6 4 2 9 2 1 6 2 9 11 12 11 1 13 1 5 1 3 10 1 2 5 4 1 5 1 3 4 3 1 2 12 1 2 14 4 0 1 1 LUTS QOL 1 LUTS LUTS 2012 5 2015 5 3 IPSS 8 LUTS 80 40 40 12 IPSS QOL UFM 8-OHdG IPSS 8-OHdG LUTS 1 30 IPSS IPSS-QOL BII score UFM 8-OHdG hanp IPSS IPSS-QOL BII score NPI 1

LUTS 1 2015 5 2 OABSS 3 2 1 1 add on 2 3 3 3 2015 QOL Quality of Life TJ-54 R 1 2.5g 1 3 12 12 OABSS 1 HUS PSQIP<0.05 24 12 74.4 9.8 3 OABSS 4.6 1.7 2.8 1.9 P<0.001 OABSS Q2 2.6 0.6 1.8 0.9 P<0.001 3.7 2.2 2.2 1.8 P<0.001 HUS 2.4 0.6 3.3 1.2 P=0.002 PSQI 7.6 3.1 5.7 1.7 P<0.001 1

2014 11 2015 10 1 LUNA 16 56.3 41 69 52 / 5 2 2 3 4 16 14 2 1 1 87%